Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited

4502

Rang in Aktien #378
Takeda Pharmaceutical Company Limited is a global biopharmaceutical enterprise... Takeda Pharmaceutical Company Limited is a global biopharmaceutical enterprise engaged in the discovery, development, manufacturing, marketing, and out-licensing of various medical products. The company's operations span Japan, the United States, Europe, Canada, Latin America, Russia, and other regions across Asia and internationally. Takeda concentrates its efforts on key therapeutic areas such as gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience. Its extensive product range includes well-known brands like Entyvio, Takhzyro, Velcade, and Vyvanse. To advance its pipeline and innovation, Takeda actively fosters numerous collaborations, in-licensing agreements, research partnerships, and strategic alliances with a diverse array of organizations, including academic institutions like the University of Texas MD Anderson Cancer Center and biotech firms such as Neurocrine Biosciences, Inc. and Arrowhead Pharmaceuticals Inc. Established in 1781, the company maintains its headquarters in Tokyo, Japan.
Aktienkurs
$40.26
Marktkapitalisierung
$64.06B
Veränderung (1 Tag)
0.71%
Veränderung (1 Jahr)
42.44%
Land
JP
Handel Takeda Pharmaceutical Company Limited (4502)

Kategorie

Healthcare
P/B-Verhältnis für Takeda Pharmaceutical Company Limited (4502)
P/B-Verhältnis zum 2026 TTM: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von Takeda Pharmaceutical Company Limited beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) 0. Am Ende des Jahres 2026 lag das P/B-Verhältnis bei 0.
P/B-Verlauf für Takeda Pharmaceutical Company Limited von 2026 bis 2026
P/B-Verhältnis zum Jahresende
Jahr P/B-Verhältnis ändert
Nicht genügend Daten für die angegebenen Daten.
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber